Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

A new era of anticoagulant therapy in the prevention of stroke in non-rheumatic atrial fibrillation

https://doi.org/10.14412/2074-2711-2012-396

Full Text:

Abstract

It is known that non-rheumatic atrial fibrillation (AF) is one of the most common types of cardiac arrhythmia and a common cause of cardiogenic cerebral embolism. Oral anticoagulant therapy is a leader in the prevention of thromboembolic events in AF. More than 60 years, only warfarin and other vitamin K antagonists (VKA) were used as oral therapy due to their extraordinary efficacy in preventing stroke and other thromboembolic events after myocardial infarction in AF and prosthetic heart valves. In addition, there are numerous problems associated with treatment with VKA, which significantly limits their widespread use. New anticoagulants, such as the oral direct thrombin inhibitor (dabigatrana etexilate) and the direct factor Xa antagonists rivaroxaban, apixaban, edoxaban, have been recently designed, clinically tested, and put into practice. The initiation of clinical use of these agents has opened up a new page of oral anticoagulant therapy in the prevention of thromboembolic events in AF.

References

1. <div><p>Feinberg W.M., Blackshear J.L., Laupasic A. et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implication. Arch Int Med 1995;155:469-73.</p><p>Go A.S., Hylek E.M., Philips K.A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.</p><p>Naccarelli G.V., Varker H., Lin J. et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.</p><p>Wolf P.A., Abbot R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Int Med 1987;147:1561-4.</p><p>Kopecky S.L., Gersh B.J., McGoon M.D. et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 1987;317:669-74.</p><p>Goldstein L.B., Bushnell Ch.D., Adams R.J. et al. Guidelines for the primary prevention of stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-84.</p><p>Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011 г. Рац фармакотер в кардиол 2011;(прил 4):3-80.</p><p>Brandt F.N., Abbot R.D., Kannel W.B. et al. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham study. JAMA 1985;254:3449-53.</p><p>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Int Med 1994;154:1449-547.</p><p>Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Int Med 1992;116:1-5.</p><p>Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: clinical features of patients at risk. Ann Int Med 1992;116:6-12.</p><p>Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.</p><p>Hart R.G., Pearce L.A., McBride R. et al. for the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999;30:1223-9.</p><p>Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263-72.</p><p>Суслина З.А., Танашян М.М., Домашенко М.А. Антитромботическая терапия ишемических нарушений мозгового кровообращения. М.: МИА, 2009;224 с.</p><p>Nelson C.W. Early dicumarol research and Mayo. Mayo Clin Proc 1996;71:220.</p><p>Cucchiara B.L., Kasner S.E. Apixaban in atrial fibrillation: from bleeding cows to 21st century medicinal chemistry. Stroke 2011;42:2376-8.</p><p>Bousser M.-G. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis 2009;27(Suppl 3):12-9.</p><p>Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-41.</p><p>Hylek E.M., Skates S.J., Sheechan M.A. et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for the patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.</p><p>Samsa G.P., Matchar D.B., Goldstein L.B. et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Int Med 2000;160:967-73.</p><p>Baker W., Cios D., Sander S. et al. Metaanalysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;3:244-52.</p><p>Гаврисюк Е.В., Игнатьев И.В., Сычев Д.А. и др. Анализ применения непрямого антикоагулянта варфарина у пациентов с постоянной формой фибрилляции предсердий в поликлинических условиях. Клин фармакол и тер 2012;1:42-7.</p><p>Bereznicki L.R.E., Peterson G.M. New Antithrombotics for atrial fibrillation. Cardiovascular therapeutics 2010;28:278-86.</p><p>Connolly S., Progue J., Hart R. et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial. Lancet 2006;367:1903-12.</p><p>Furie K.L., Kasner S.E., Adams R.J. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. AHA/ASA Guideline. Stroke 2011;42:227-76.</p><p>Holmes D.R., Reddy V.Y., Turi Z.G. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for the prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 2009;374:534-42.</p><p>Camm A.J., Lip G.Y.H., De Caterina R. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012 www.escardio.org/guidelines</p><p>Alkins P.T., Feldman H.A., Zoble R.G. et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation pooled analysis of SPORTIF III and V clinical trials. Stroke 2007;38:874-80.</p><p>Ellis D.J., Usman M.H., Milner P.G. et al. The first evaluation of novel vitamin K antagonist, Tecarfarin (ATI-5923) in patients with atrial fibrillation. Circulation 2009;120:1029-35.</p><p>Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.</p><p>Парфенов В.А., Вербицкая С.В. Новые возможности профилактики инсульта при фибрилляции предсердий. Неврол нейропсихиатр и психосом 2012;1:36-42.</p><p>Oldgren J., Alings M., Darius H. еt al. Dabigatran versus warfarin in atrial fibrillation patients with low, moderate and high CHADS2 score: a RE-LY subgroup analysis. JACC 2010;55:A1.</p><p>Diener H-C., Connolly S.J., Ezekowitz M.D. еt al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurology 2010;9:1157-63.</p><p>Kubitza D., Becka M., Roth A. et al. Doseescalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65.</p><p>ROCKET AF Study Investigators. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159(3):340.e1-347.e1.</p><p>Patel M.R., Mahaffey K.W., Gard J. et al. Rivaroxaban vs Warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.</p><p>Granger Ch.B., Alexander J.H., McMurray J.J. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.</p><p>Guyatt G.H., Akl E.A., Crowther M. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012;141(Suppl):7S-47.</p><p>Furie K.L., Goldstein L. B., Albers G.W. et al. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2012;43:in press.</p><p>Granger Ch.B., Armaganijan L.V. Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism? Circulation 2012;125:159-64.</p><p>Wallentin L., Yusuf S., Ezekowitz M.D. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.</p></div><br />


For citation:


Fonyakin A.V., Geraskina L.A. A new era of anticoagulant therapy in the prevention of stroke in non-rheumatic atrial fibrillation. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(3):15-19. (In Russ.) https://doi.org/10.14412/2074-2711-2012-396

Views: 369


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)